510(k) device
cCeLL - In vivo
VPIX Medical, Inc. · Endoscope, Neurological (GWG, Class II) · First FDA decision Aug 21, 2024, newest Oct 16, 2026Brain tumorsHydrocephalus
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
2
Naming "cCeLL"
MAUDE reports
0
Brand "cCeLL", since 2015
PubMed studies
1,024
Mentioning "cCeLL"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing cCeLL - In vivo
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 2 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "cCeLL", any status and sponsor, newest update first.
VPIX MedicalNot on our public-company list
NCT07254845 · 30 participants (planned) · Start Dec 1, 2025 · Primary completion May 30, 2026
Device: cCeLL In vivo · For: Frozen Sections; Indocyanine Green (ICG); Brain Tumor
- Multi-center Study on CCeLL-In Vivo's Clinical Efficacy for Intraoperative Brain Tumor Diagnosis.Not yet recruiting
VPIX MedicalNot on our public-company list
NCT06867978 · 100 participants (planned) · Start Jun 1, 2025 · Primary completion Jun 30, 2026
Device: cCeLL In vivo · For: Frozen Sections; Indocyanine Green; Brain Tumor
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "cCeLL", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code GWG
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "cCeLL"[tiab]. The summary above synthesizes these.
- (E)-1,2-Bis(1-propyl-5,6-dimethyl-1H-benzimidazol-2-yl)ethene.
Stibrany RT, Potenza JA · Acta Crystallogr Sect E Struct Rep Online · 2010
- C-cell hyperplasia.
Guyétant S, Bléchet C, Saint-André JP · Ann Endocrinol (Paris) · 2006Review
- 1-(4-methylamino-1,2,5-thiadiazole-3-carbonyl)thiosemicarbazide.
Fonari MS, Simonov YA, Lipkowski J, et al. · Acta Crystallogr C · 2003
- [Endocrine and neuroendocrine tumors].
Riss P, Scheuba K, Strobel O · Chirurg · 2021Review
- Standing thyroidectomy in 10 horses.
Marcatili M, Voss SJ, Pollock PJ · Vet Surg · 2018
- Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
Bjerre Knudsen L, Madsen LW, Andersen S, et al. · Endocrinology · 2010Clinical Trial
- Intragenic mutations in thyroid cancer.
Sobrinho-Simões M, Máximo V, Rocha AS, et al. · Endocrinol Metab Clin North Am · 2008Research Support, Non-U.S. Gov't, Review
- [Malignant ovarian struma].
Ermilova VD, Smirnova EA, Barinov VV · Arkh Patol · 1990Case Reports, English Abstract
- Thyroid C-Cell Biology and Oncogenic Transformation.
Cote GJ, Grubbs EG, Hofmann MC · Recent Results Cancer Res · 2015Research Support, N.I.H., Extramural, Review
- Thyroid C-Cell Biology and Oncogenic Transformation.
Bagheri-Yarmand R, Grubbs EG, Hofmann MC · Recent Results Cancer Res · 2025Review
- C-cell hyperplasia.
Albores-Saavedra J · Am J Surg Pathol · 1989Letter, Comment
- A pre-vertebrate endodermal origin of calcitonin-producing neuroendocrine cells.
Rees JM, Kirk K, Gattoni G, et al. · Development · 2024
Other devices of this type
Also filed under product code GWG.
- Aurora Surgiscope SystemRebound Therapeutics Corporation · 510(k) 2023
- QEVO SystemCarl Zeiss Meditec, AG · 510(k) 2023
- Apollo SystemPenumbra, Inc. · 510(k) 2016
- MINOP Disposable Introducer 26FAesculap, Inc. · 510(k) 2014
- KARL STORZ Flexible Video Neuro-EndoscopeKarl Storz SE & CO. KG · 510(k) 2026
- Precision S 4K SinuscopeStryker Endoscopy · 510(k) 2026
- Hydro Irrigation SystemStryker Instruments · 510(k) 2026
- HJY VisualNext 3D Endoscopic Vision SystemHjy Smart Medical Device Co., Ltd. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.